SureTrader Advertisement Advertisement Advertisement
Home > Boards > US OTC > Medical - Drugs >


Add AVXT Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator johnny canuck, Rookiemove
Search This Board:
Last Post: 11/25/2015 10:26:06 PM - Followers: 30 - Board type: Free - Posts Today: 0


Industry Center - Biotechnology

Contact Information
Address: 2000 Hamilton St., Ste. 204
Philadelphia, PA 19130
Phone: 215-241-9760
Fax: 215-241-9684
Key People
CEO: Adele Sommerfeld
BOD: Andrew W. Dahl Sc.D.; Serge Morrell
AVAX Technologies wants to turn cancer cells into cancer fighters. The company is developing vaccines created by extracting a patient's own cancer cells and chemically treating them to induce an immune system response. The technology used to create the vaccines (called AC Vaccine) is licensed from Thomas Jefferson University. AVAX's lead vaccine candidate MVax is intended as a treatment for late-stage melanoma. The company is also developing vaccine candidates to fight ailments such as ovarian cancer (OVax) and non-small cell lung cancer (LungVax).
Business Summary  

AVAX Technologies, Inc., a development stage biotechnology company, together with its subsidiaries, engages in the development and future commercialization of individualized vaccine therapies and other technologies for the treatment of cancer in the United States and Europe. The company's autologous cell vaccine candidates include M-Vax under Phase III clinical status, which is used for the treatment of melanoma; L-Vax under Phase I-II clinical status that is used for the treatment of non-small cell lung cancer; and O-Vax under Phase I-II clinical status, which is used for the treatment of ovarian cancer. It also offers biological manufacturing services to other biotechnology and pharmaceutical companies; and contract manufacturing services in for cell and gene therapy, and biological products in France. AVAX Technologies, Inc. was founded in 1990 and is based in Philadelphia, Pennsylvania.


AVAX Technologies, Inc. Files Form 10 With SEC

Press Release Source: AVAX Technologies, Inc. On Friday February 4, 2011, 12:41 pm EST

PHILADELPHIA, Feb. 4, 2011 /PRNewswire/ -- AVAX Technologies, Inc. (Pink - News) ("AVAX" or the "Company") today announced that it filed a Form 10 with the Securities and Exchange Commission ("SEC").  Upon the effectiveness of this Form 10, AVAX will once again become a publicly reporting company.  The Company intends to seek to have its common stock trade on the Over-the-Counter Bulletin Board.

The Company's Form 10, which contains among other things, recent information about the Company's business, operations, financial results and capitalization, can be accessed through the website maintained by the SEC at

About AVAX Technologies, Inc.

AVAX Technologies, Inc. is a biotechnology company headquartered in Philadelphia, PA.   The Company is engaged in the research and clinical and commercial development of biological products and cancer therapeutics.

The Company's AC Vaccine platform is a therapeutic cancer vaccine.

Forward-Looking Statements

Certain statements in this release are "forward-looking" statements.   Forward-looking statements involve significant risks and uncertainties, and in light of the significant uncertainties inherent in such statements, the inclusion of such information should not be regarded as a representation by the Company that the objectives and plans of the Company will be achieved. In fact, actual results could differ materially from those contemplated by such forward-looking statements. These statements include, but are not limited to, the Company's immediate need to obtain additional funding to continue to finance the Company, the Company's plans, objectives, projections, expectations and intentions such as those relating to the future development of M-VAX® and its other vaccine candidates, as well as other important factors discussed in the Company's Form 10.   The Company does not undertake any obligation to release publicly any revisions to these forward-looking statements or to reflect the occurrence of unanticipated events. 


Press Releases & AVAX Information:

2/4/2001: AVAX Technologies, Inc. Files Form 10 With SEC

AVAX Announces Settlement Agreement with Cancer Treatment Centers of America and Approves $45 Million Private Placement Financing


Published: Aug 4, 2015 7:31 p.m. ET


PHILADELPHIA, Aug 04, 2015 (BUSINESS WIRE) -- AVAX Technologies, Inc., (“AVAX” or “The Company”) (AVXT – OTCMKTS), a leading developer of proprietary cancer immunotherapy products, has signed a Settlement & Release Agreement with Cancer Treatment Centers of America Inc. (“CTCA”) to positively resolve the existing debt obligations owed to CTCA.

Under the terms of the Settlement Agreement, CTCA has agreed to settle its $5,826,464.73 Judgment against AVAX in exchange for 860,000 Series A Convertible Preferred Shares at a consideration of $5.00 per share, and a one-time payment of $1.5 million in cash. Firebird Management, a shareholder and a creditor of AVAX, has agreed to swap its outstanding debt for the Series A Convertible Preferred Shares also at a consideration of $5.00 per share.

Andrew Dahl, AVAX Board Member noted, “we are extremely happy to be able to move forward with the reorganization of AVAX’s balance sheet and look forward to re-commencing the important planned clinical trials at AVAX. Our previous work with CTCA on clinical programs has been very successful.”

Richard Rainey, Acting Chief Executive Officer of AVAX, stated, “We are pleased that throughout the development of our AC Vaccine® platform, all of our data has remained consistently positive and has supported further development of the treatment. We feel our immunotherapy platform is consistent with recently approved products and could be additive to the benefits achieved in helping patients with cancer.”

SGC Canada Inc., is acting on behalf of AVAX with its creditors in negotiating its informal restructuring plan. David Holden, the Senior Corporate Advisor of SGC states that “AVAX will be effectively debt-free once the Financial Restructuring & Refinancing Plan is completed.” The Board of AVAX has previously approved the engagement of Phoenix Corporate Finance Inc., a corporate finance firm which specializes in alternative financing, to advise, structure, and facilitate the distribution of a proposed Private Placement financing. through select securities dealers in the US and Canada. AVAX intends to raise $45 million to fund its next round of clinical testing through the issuance of the Series A Convertible Preferred Shares.




  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
#1190  Sticky Note NEWS: HandyMan2000 10/19/15 08:52:59 AM
#1259   They sell in the morning not "short it". bayetta 11/25/15 10:26:05 PM
#1258   Tradition lately is to whack it (short it) johnny canuck 11/25/15 06:12:30 PM
#1257   If it is going to keep tradition, it Jemmani 11/25/15 02:27:46 PM
#1256   Very nice ask slapping today, gapping the hell Rookiemove 11/25/15 12:50:27 PM
#1255   You guys are dreaming. KBIO has 4M shares bayetta 11/24/15 10:22:15 PM
#1254   That is pretty impressive stuff!! Would love Rookiemove 11/23/15 12:43:42 PM
#1253   never give up, pray always. You never know akiaki 11/23/15 12:32:32 PM
#1252   Is the Yahoo message thread dead? bayetta 11/22/15 09:49:29 PM
#1251   I hear you. Watched by my Mom katter 11/20/15 10:05:05 AM
#1250   Been waiting for such about 18 years. Why Geoman1 11/19/15 02:26:50 PM
#1249   We are all in anticipation -mode, no selling, Rookiemove 11/19/15 11:55:29 AM
#1248   I think Yahoo message board is toast. bayetta 11/18/15 10:26:37 PM
#1247   I see no reason that AVXT can't have Rookiemove 11/16/15 02:04:17 PM
#1246   Hope she doesn't become a hatchet lady and Geoman1 11/16/15 02:01:40 PM
#1245   Welcome Geoman, I'm in for only 8 years FiftyFifty 11/16/15 01:06:10 PM
#1244   Finally joining the watchers' circle. Hoping the big Geoman1 11/16/15 12:45:45 PM
#1243   Just playing the spread.......low volume games here. Rookiemove 11/09/15 03:17:23 PM
#1242   AVXT just begging for news! ! Rookiemove 11/09/15 02:25:10 PM
#1241   Looks like the games are afoot again. johnny canuck 11/06/15 03:47:10 PM
#1240   Good Volume today. johnny canuck 11/06/15 03:14:46 PM
#1239   When we see news with Financing secured, Katie Rookiemove 11/05/15 09:32:53 AM
#1238   Thanks MYMO, johnny canuck 11/05/15 08:58:46 AM
#1237 mymovado1 11/05/15 08:10:48 AM
#1236   On another board people are saying they can't Jemmani 11/05/15 12:17:55 AM
#1235   Hahahahahahahahaha!!!!!!!!!! Someone just sold "272" shares to drop it johnny canuck 11/04/15 09:45:14 AM
#1234   Hey, we got a buyer!! GO AVXT !! Rookiemove 11/03/15 01:04:09 PM
#1233   We have no heartbeat today! Need some buyers Jemmani 11/03/15 12:11:04 PM
#1232   AVX T 2000 was a very good year! Rookiemove 11/03/15 08:46:03 AM
#1231   May 15, 1997 high 5.00 11,100 volume katter 11/02/15 07:49:37 PM
#1230   News has to be soon! Hopefully these dings Jemmani 11/02/15 10:37:12 AM
#1229   Impossible to tell, but my thoughts, barring a Rookiemove 10/30/15 12:44:43 PM
#1228   where do you see this stock price if akiaki 10/30/15 12:10:45 PM
#1227   Yes sir, Fridays are typically good to AVXT !! Rookiemove 10/30/15 09:28:39 AM
#1226   Let's have a good Friday AVXT! Jemmani 10/30/15 09:00:38 AM
#1225   We have a bipolar chart going!! Looks Rookiemove 10/29/15 03:55:17 PM
#1224   Bid is stacking nicely! Volume is getting better Jemmani 10/29/15 02:14:21 PM
#1223   Oh SNAP!! 330K ON BID AT .0220 Rookiemove 10/29/15 09:49:40 AM
#1222   Week starting off decent. With good volume! Jemmani 10/27/15 10:31:54 AM
#1221   I think STXG trying to cover, could get Rookiemove 10/26/15 02:38:39 PM
#1220   Longs getting tired of the short games here. Rookiemove 10/26/15 01:04:29 PM
#1219   Nice bids!! Lets close this Friday strong!! GO Rookiemove 10/23/15 01:05:50 PM
#1218   A) The CEO does not work for Phoenix mymovado1 10/22/15 02:54:24 PM
#1217   Nice movement today. AVXT getting some traction. Rookiemove 10/22/15 12:40:32 PM
#1216   You obviously have not been following the pharma medimpact 10/22/15 12:14:29 PM
#1215   Quite likely will be a R/S to achieve Rookiemove 10/22/15 08:07:30 AM
#1214   BTW, Avax could never be a billion dollar bayetta 10/22/15 01:13:02 AM
#1213   Keep it a real around here guys. bayetta 10/22/15 01:07:04 AM
#1212   From .023, a Ten Bagger would be .23. Rookiemove 10/21/15 06:27:48 PM
#1211   .25 or higher certainly possible. When Rookiemove 10/21/15 06:08:35 PM
#1210   Is this the initial porice and you are katter 10/21/15 06:05:35 PM